An EpCAM-binding variant of inRas37 for treatment of pancreatic cancers was developed by simply swapping the integrin-binding peptide with an EpCAM-recognizing cyclic peptide [259]. This evidence concerns the gene EPCAM and pancreatic neoplasm.